J. Pers. Med. 2014, 4(1), 79-87; https://doi.org/10.3390/jpm4010079
DTC-and-Me: Patient, Provider, Proteins and Regulators
SomaLogic Inc., 2945 Wilderness Pl., Boulder, CO 80301, USA
*
Author to whom correspondence should be addressed.
Received: 13 December 2013 / Revised: 6 March 2014 / Accepted: 7 March 2014 / Published: 18 March 2014
(This article belongs to the Special Issue Bringing Personalized Medicine into Clinical Practice 2013)
Abstract
The yet-unrealized potential for more “personalized” Direct-to-Consumer (DTC) tests to fundamentally alter the practice and economics of healthcare is undeniable. However, there are also many challenges to be met, including the herculean task of ensuring that the information provided by such tests is scientifically sound and, ideally, medically actionable. We consider recent events in DTC testing and suggest a “thought experiment” of an approach that could ultimately meet the needs of patients, providers and regulatory authorities. View Full-TextKeywords:
proteomics; personalized medicine; SOMAmer; aptamer; SOMAscan; diagnostics; direct-to-consumer
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Steele, F.R.; Gold, L. DTC-and-Me: Patient, Provider, Proteins and Regulators. J. Pers. Med. 2014, 4, 79-87.
Related Articles
Article Metrics
Comments
[Return to top]
J. Pers. Med.
EISSN 2075-4426
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert